SBRT 2016

Drugs, SBRT and Oligometastases • Ongoing studies with VEGFI, TKI, Interleukin ...... are evaluating – increase therapeutic efficacy – Pattern of failure – Fractionation schedules / target volumes – Treatment response – Side effects • No clear data • Good experience with conventional fractionation in combination with Chemo or new biological agences have to be analysed carefull with SBRT • Studies have to be performed